Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Zai Lab Limited

Market Cap 1.98B 1.71B 1.58B 1.48B 2.77B 190B 2.81B 18.68B 7.27B 91.47B 7.44B 7.28B 317B P/E Ratio 2026 *
-7.97x
P/E Ratio 2027 * -9.46x
Enterprise Value 1.54B 1.33B 1.22B 1.15B 2.15B 147B 2.18B 14.51B 5.64B 71.02B 5.78B 5.65B 246B EV / Sales 2026 *
3.43x
EV / Sales 2027 * 2.68x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 60 2014-03-31
Director/Board Member 82 2016-12-31
Director/Board Member 74 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.94B
+1.63%-1.21%+16.80%-18.09% 61.21B
+2.50%+7.58%+64.44%+216.37% 58.15B
-0.92%+28.60%+28.60%+28.60% 39.54B
+4.16%+16.25%-56.08%-64.88% 35.08B
+2.94%+2.04%+47.58%-35.26% 28.68B
+2.32%+10.05%+53.89%+76.65% 21.06B
+7.94%+1.18%+79.34%-59.73% 18.25B
-1.88%-5.07%-10.05%+93.76% 16.49B
+0.78%+0.78%+49.83%+98.01% 15.87B
Average +1.11%+1.25%+30.48%+37.27% 32.7B
Weighted average by Cap. +1.56%+1.44%+28.92%+43.98%

Financials

2026 *2027 *
Net sales 449M 388M 357M 334M 627M 42.96B 637M 4.23B 1.65B 20.71B 1.68B 1.65B 71.82B 596M 514M 473M 444M 832M 57.03B 845M 5.61B 2.18B 27.49B 2.24B 2.19B 95.33B
Net income -241M -208M -191M -180M -336M -23.07B -342M -2.27B -883M -11.12B -904M -885M -38.56B -156M -135M -124M -117M -218M -14.98B -222M -1.47B -574M -7.22B -587M -575M -25.05B
Net Debt -443M -383M -352M -330M -619M -42.43B -629M -4.18B -1.62B -20.45B -1.66B -1.63B -70.93B -387M -334M -308M -289M -541M -37.07B -549M -3.65B -1.42B -17.87B -1.45B -1.42B -61.97B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!